48
Participants
Start Date
December 6, 2021
Primary Completion Date
February 28, 2024
Study Completion Date
February 21, 2025
Pfizer-BioNTech COVID-19 Vaccine 2023-2024
Administration: One dose administered intramuscularly.
Moderna COVID-19 Vaccine 2023-2024
Administration: One dose administered intramuscularly.
SOC IS Regimen
Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.
SOC IS Reduction
Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.
NYU Langone Transplant Institute, New York
Mt. Sinai Hospital, New York
Weill Cornell Medicine, New York
University of Pittsburgh, Pittsburgh
University of Pennsylvania, Philadelphia
Johns Hopkins Institute for Clinical and Translational Research: Broadway Adult Outpatient Clinical Research Unit, Baltimore
Emory Healthcare, Atlanta
University of Iowa Hospitals, Iowa City
University of Wisconsin-Madison, Madison
Northwestern University, Evanston
University of Illinois Health, Chicago
Ochsner Health, New Orleans
Houston Methodist, Houston
University of California, San Diego, San Diego
University of California San Francisco Health, San Francisco
Collaborators (1)
PPD Development, LP
INDUSTRY
Johns Hopkins University
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH